Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
NPJ Breast Cancer|August 8, 2022
Acute health-related quality of life outcomes and systemic inflammatory markers following contemporary breast cancer surgeryArielle S Radin, Julienne E Bower, Michael R Irwin, et al.
Cancer|February 19, 2021
Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancerJulienne E Bower, Patricia A Ganz, Michael R Irwin, et al.
Cancer|December 19, 2018
Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancerJulienne E Bower, Arash Asher, Deborah Garet, et al.
Cancer|October 6, 2025
Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examinationJulienne E Bower, Arielle Radin, Patricia A Ganz, et al.
Springerplus|May 27, 2014
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancerSara A Hurvitz, Linda D Bosserman, David Chan, et al.
NPJ Breast Cancer|April 25, 2024
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancerSara A Hurvitz, Aditya Bardia, Kevin Punie, et al.
Breast Cancer Research : BCR|January 11, 2023
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)Sanne L de Haas, Dennis J Slamon, Miguel Martin, et al.
BMC Cancer|June 5, 2016
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancerKathy Miller, Javier Cortes, Sara A Hurvitz, et al.
Therapeutic Advances in Medical Oncology|December 10, 2020
Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimusParvin F Peddi, Merry Tetef, Paul Coluzzi, et al.
Cancer Management and Research|November 10, 2021
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast CancerPeter A Fasching, Thomas E Delea, Yen-Shen Lu, et al.
Pageof 14